الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> mGluR >>RO0711401

RO0711401

رقم الكتالوجGC63173

RO0711401 عبارة عن مُعدِّل خيفي انتقائي نشط عن طريق الفم لمستقبل mGlu1 مع EC50 قدره 56 نانومتر

Products are for research use only. Not for human use. We do not sell to patients.

RO0711401 التركيب الكيميائي

Cas No.: 714971-87-6

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
116٫00
متوفر
5 mg
105٫00
متوفر
10 mg
175٫00
متوفر
25 mg
385٫00
متوفر
50 mg
595٫00
متوفر
100 mg
945٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

RO0711401 is a selective and orally active positive allosteric modulator of mGlu1 receptor with an EC50 of 56 nM[1][2].

RO0711401 (10 mg/kg; s.c.; once) causes a long-lasting improvement in motor performance, which is maintained to the same extent at least for 6 days[1].Systemic injection of RO0711401 is shown to reduce the frequency of spike-and-wave discharges in a rat model of absence epilepsy, and to improve motor signs in autoimmune encephalomyelitis (EAE) mice[1].

[1]. Serena Notartomaso, et al. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol Brain. 2013 Nov 19;6:48.
[2]. Eric Vieira, et al. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9.

مراجعات

Review for RO0711401

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RO0711401

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.